Welcome to Markets Desk, your midday read on what's moving the needle.
Adidas is feeling the burn after a strong World Cup showing failed to impress investors. The sportswear giant's stock dropped seventeen percent after the company disclosed a thirty percent surge in marketing expenditure. Winning on the pitch didn't translate to winning on the balance sheet, and the market punished that gap hard.
Shifting to biotech, Ocugen received a significant regulatory tailwind today as the FDA granted Regenerative Medicine Advanced Therapy designation to its OCU four ten treatment for geographic atrophy, a severe complication of dry age-related macular degeneration. RMAT status accelerates the path to approval and signals the agency sees real promise in the therapy, a meaningful catalyst for a small-cap name in a high-need space.
And on the speculative side, prediction market platform Kalshi is now pricing a seventy-four percent probability that SpaceX and Tesla merge before May first, two thousand twenty seven. Wall Street remains deeply skeptical. The structural, regulatory, and governance hurdles are formidable, and as analysts note, combining two troubled narratives doesn't automatically produce a stronger one.
That's the tape. Markets Desk, signing off the floor.
